Non-alcoholic Fatty Liver Disease and the Gut Microbiota: Exploring the Connection
DOI:
https://doi.org/10.17140/GOJ-1-107Keywords:
Non-alcoholic fatty liver disease, Microbiota, Insulin resistance, Metabolic syndrome, Steatohepatitis, InflammosomesAbstract
As the gut microbiota continues to be implicated in an increasing number of disease processes, a plethora of new literature surrounding its complexity and role in the maintenance of intestinal homeostasis has become available. Non-alcoholic fatty liver disease (NAFLD) has become the most common nonviral liver disease worldwide and a number of predisposing risk factors for NAFLD have been identified, including obesity and insulin resistance. Recent evidence supports a role for the gut microbiota in the pathogenesis of these risk factors and NAFLD, itself. Additionally, changes in the gut microbiota can lead to activation of immune responses that have the potential to promote progression of NAFLD to the more severe Non alcoholic steatohepatitis (NASH). Furthermore, the gut microbiota may serve as a potential target for therapeutic options to treat NAFLD. This review seeks to explain the role of the gut microbiota in the pathogenesis of NAFLD and its risk factors, while also discussing potential future treatment options directed at correcting imbalances with in the gut microbiota.
References
Arab JP, Candia R, Zapata R, et al. Management of Non-al-coholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol. 2014; 20: 12182-12201. doi: 10.3748/wjg.v20.i34.12182
Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver dis-ease: What the clinician needs to know. World J Gastroenterol. 2014; 20: 12956-12980. doi: 10.3748/wjg.v20.i36.12956 -78,79 81-83 -
Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver dis-ease. BMJ. 2014; 347: g4596-g4596. doi: 10.1136/bmj.g4596
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the Amer-ican Gastroenterological Association. Hepatology. 2012; 55: 2005-2023. doi: 10.1002/hep.25762
Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect. 2013; 19: 338-348. doi: 10.1111/1469- 0691.12140
Giorgio V, Alisi A, Kazem HM, Monti S, Nobili V. NASH and the Cross-Talk Between the Gut and Liver. Curr Pediatr Rep. 2014; 2: 211-217. doi: 10.1007/s40124-014-0047-7
Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of in-dividuals with Non-alcoholic fatty liver disease. Gastroenterol-ogy. 2014; 146: 726-735. doi: 10.1053/j.gastro.2013.11.049
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with Non-alcoholic fatty liver disease. J Clin Invest. 2005; 115: 1343-1351. doi: 10.1172/ JCI200523621
Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxida-tive stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752-1761. doi: 10.1172/JCI200421625
Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013; 4: 93. doi: 10.3389/fendo.2013.00093
Gangarapu V, Yıldız K, Ince AT, Baysal B. Role of gut mi-crobiota: obesity and NAFLD. Turk J Gastroenterol. 2014; 25: 133-140. doi: 10.5152/tjg.2014.7886
Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in Non-alcoholic fatty liver disease. World J Gastroen-terol. 2014; 20: 7381-7391. doi: 10.3748/wjg.v20.i23.7381
Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic his-tology in obese patients undergoing bariatric surgery. J Hepatol. 2006; 45: 600-606. doi: 10.1016/j.jhep.2006.06.013
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330-344. doi: 10.1038/ nrgastro.2013.41
Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascu-lar disease among type 2 diabetic patients. Diabetes Care. 2007; 2007: 1212-1218. doi: 10.2337/dc06-2247
Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol. 2014; 29: 1139-1148. doi: 10.1111/jgh.12556
Turnbaugh PJ, Ley RE, Mahowald M a, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with in-creased capacity for energy harvest. Nature. 2006; 444: 1027- 1031. doi: 10.1038/nature05414
Ley R, Backhed F, Turnbaugh P, Lozupone C, Knight R, Gordon J. Obesity alters gut microbial ecology. PNAS. 2005; 102: 11070-11075. doi: 10.1073/pnas.0504978102
Musso G, Gambino R, Cassader M. Gut microbiota as a reg-ulator of energy homeostasis and ectopic fat deposition: mecha-nisms and implications for metabolic disorders. Curr Opin Lipi-dol. 2010; 21: 76-83. doi: 10.1097/MOL.0b013e3283347ebb
Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. 2011; 121: 2126-2132. doi: 10.1172/JCI58109
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecol-ogy: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023. doi: 10.1038/4441022a
Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010; 18: 190-195. doi: 10.1038/oby.2009.167
Duncan SH, Lobley GE, Holtrop G, et al. Human colonic mi-crobiota associated with diet, obesity and weight loss. Int J Obes (Lond). 2008; 32: 1720-1724. doi: 10.1038/ijo.2008.155
Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473: 174-180. doi: 10.1038/nature09944
Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101: 15718-15723. doi: 10.1073/ pnas.0407076101
Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007; 104: 979-984. doi: 10.1073/pnas.0605374104
Zhang H, DiBaise JK, Zuccolo A, et al. Human gut micro-biota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009; 106: 2365-2370. doi: 10.1073/pnas.0812600106
Parekh PJ, Arusi E, Vinik AI, Johnson D a. The role and influence of gut microbiota in pathogenesis and management of obesity and metabolic syndrome. Front Endocrinol (Lausanne). 2014; 5: 47. doi: 10.3389/fendo.2014.00047
Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013; 2013: 39-58. doi: 10.1016/j.mam.2012.11.001
Lin HV, Frassetto A, Kowalik EJ, et al. Butyrate and pro-pionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mecha-nisms. PLoS One. 2012; 7(4): e35240. doi: 10.1371/journal. pone.0035240
Caricilli AM, Picardi PK, de Abreu LL, et al. Gut micro-biota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 2011; 9(12): e1001212. doi: 10.1371/journal. pbio.1001212
Spor A, Koren O, Ley R. Unravelling the effects of the en-vironment and host genotype on the gut microbiome. Nat Rev Microbiol. 2011; 9: 279-290. doi: 10.1038/nrmicro2540
Raso GM, Simeoli R, Iacono A, et al. Effects of a Lacto-bacillus paracasei B21060 based synbiotic on steatosis, in-sulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014; 25: 81-90. doi: 10.1016/j. jnutbio.2013.09.006
CaricilliAM,SaadMJA.Theroleofgutmicrobiotaoninsulinre-sistance.Nutrients.2013;2013:829-851.doi:10.3390/nu5030829
Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC, et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007; 56: 1986-1998. doi: 10.2337/db06-1595
Chung S, LaPoint K, Martinez K, Kennedy A, Sandberg MB, McIntosh MK. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology. 2006; 147: 5340-5351. doi: 10.1210/en.2006-0536
Carvalho-filho MA, Ueno M, Hirabara SM, et al. S-Nitro-sation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: A novel mechainism of insulin resistance. Diabeteses. 2005; 54: 959-967. doi: 10.2337/diabetes.54.4.959
Schertzer JD, Klip A. Give a NOD to insulin resistance. AJP Endocrinol Metab. 2011; 2011: E585-E586. doi: 10.1152/ ajpendo.00362.2011
Zhao L, Hu P, Zhou Y, Purohit J, Hwang D. NOD1 activation induces proinflammatory gene expression and insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2011; 301: E587-E598. doi: 10.1152/ajpendo.00709.2010
Tamrakar AK, Schertzer JD, Chiu TT, et al. NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology. 2010; 151: 5624-5637. doi: 10.1210/en.2010-0437
Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999; 277: E1-E10.
Amar J, Chabo C, Waget A, et al. Intestinal mucosal adher-ence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treat-ment. EMBO Mol Med. 2011; 3: 559-572. doi: 10.1002/em-mm.201100159
Day C, James O. Steatohepatitis: a tale of two “hits”? Gas-troenterology. 1998; 114: 842-845. doi: 10.1016/S0016-5085- (98)70599-2
Tilg H, Moschen AR. Evolution of inflammation in Non-al-coholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010; 52: 1836-1846. doi: 10.1002/hep.24001
Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The in-flammasome: a caspase-1-activation platform that regulates im-mune responses and disease pathogenesis. Nat Immunol. 2009; 10: 241-247. doi: 10.1038/ni.1703
Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High Fat Diet-In-duced Gut Microbiota Exacerbates Inflammation and Obesity in Mice via the TLR4 Signaling Pathway. PLoS One. 2012; 7(10): e47713. doi: 10.1371/journal.pone.0047713
Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, All-man M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007; 47: 571-579. doi: 10.1016/j. jhep.2007.04.019
Csak T, Velayudham A, Hritz I, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression at-tenuates Non-alcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G433-G441. doi: 10.1152/ajpgi.00163.2009
Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the develop-ment of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia. 2007; 50: 1267-1276. doi: 10.1007/ s00125-007-0654-8
Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to low-dose endotoxin during progression to Non-alcoholic steato-hepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012; 16: 44-54. doi: 10.1016/j.cmet.2012.05.012
Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J He-patol. 2009; 51: 168-175. doi: 10.1016/j.jhep.2009.02.032
Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in Non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013; 2013: 20704-20728. doi: 10.3390/ijms141020704
Creely SJ, McTernan PG, Kusminski CM, et al. Lipopoly-saccharide activates an innate immune system response in hu-man adipose tissue in obesity and type 2 diabetes. Am J Phys-iol Endocrinol Metab. 2007; 292: E740-E747. doi: 10.1152/ ajpendo.00302.2006
Ye D, Li FYL, Lam KSL, et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut. 2012; 2012: 1058- 1067. doi: 10.1136/gutjnl-2011-300269
Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010; 139: 323.e7-334.e7. doi: 10.1053/j.gastro.2010.03.052
Ehses JA, Meier DT, Wueest S, et al. Toll-like receptor 2-de-ficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia. 2010; 53: 1795-1806. doi: 10.1007/s00125-010-1747-3
Himes RW, Smith CW. Tlr2 is critical for diet-induced meta-bolic syndrome in a murine model. FASEB J. 2010; 24: 731-739. doi: 10.1096/fj.09-141929
Rivera CA, Gaskin L, Allman M, et al. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastro-enterol. 2010; 10: 52. doi: 10.1186/1471-230X-10-52
Szabo G, Velayudham A, Romics Jr. L, Mandrekar P. Mod-ulation of non-alcoholic steatohepatitis by pattern recogni-tion receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res. 2005; 29: 140S-145S. doi: 10.1097/01. alc.0000189287.83544.33
Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 con-trols mucosal inflammation by regulating epithelial barrier func-tion. Gastroenterology. 2007; 132: 1359-1374. doi: 10.1053/j. gastro.2007.02.056
Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science (80- ). 2010; 328: 228-231. doi: 10.1126/sci-ence.1179721
Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011; 145: 745-757. doi: 10.1016/j.cell.2011.04.022
Chen GY, Liu M, Wang F, Bertin J, Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Im-munol. 2011; 186: 7187-7194. doi: 10.4049/jimmunol.1100412
Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-me-diated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482: 179-185. doi: 10.1038/nature10809
Wlodarska M, Thaiss CA, Nowarski R, et al. NLRP6 inflam-masome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell. 2014; 156: 1045- 1059. doi: 10.1016/j.cell.2014.01.026
Anand PK, Malireddi RKS, Lukens JR, et al. NLRP6 nega-tively regulates innate immunity and host defence against bac-terial pathogens. Nature. 2012; 488: 389-393. doi: 10.1038/na-ture11250
Salles J, Tardif N, Landrier JF, et al. TNFα gene knockout differentially affects lipid deposition in liver and skeletal muscle of high-fat-diet mice. J Nutr Biochem. 2012; 23: 1685-1693. doi: 10.1016/j.jnutbio.2011.12.001
Kamari Y, Shaish A, Vax E, et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepa-titis and liver fibrosis in hypercholesterolemic mice. J Hepatol. 2011; 55: 1086-1094. doi: 10.1016/j.jhep.2011.01.048
Cani PD, Bibiloni R, Knauf C, et al. Changes in gut mi-crobiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57: 1470-1481. doi: 10.2337/db07-1403
Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol. 2008; 48: 983-992. doi: 10.1016/j. jhep.2008.01.035
Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and mini-mal hepatic encephalopathy. PLoS One. 2013; 8: e60042. doi: 10.1371/journal.pone.0060042
Bajaj JS, Hylemon PB, Younossi Z. The Intestinal Microbi-ota and Liver Disease. Am J Gastroenterol Suppl. 2012; 1: 9-14. doi: 10.1038/ajgsup.2012.3
Kalambokis G, Tsianos E. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology. 2012; 55: 655-656. doi: 10.1002/hep.24751
Clinical Trails.gov. Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients. Website: https://clinicaltrials.gov/ ct2/show/NCT02009592. 2014; Accessed 2014.
Gibson GR, Roberfroid MB. Dietary modulation of the hu-man colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125: 1401-1412.
Gibson GR, Probert HM, Loo J Van, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: up-dating the concept of prebiotics. Nutr Res Rev. 2004; 17: 259- 275. doi: 10.1079/NRR200479
Slavin J. Fiber and prebiotics: mechanisms and health ben-efits. Nutrients. 2013; 5: 1417-1435. doi: 10.3390/nu5041417
Parnell J a, Raman M, Rioux KP, Reimer R a. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012; 32: 701-711. doi: 10.1111/j.1478- 3231.2011.02730.x
Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther. 2006; 24: 701-714. doi: 10.1111/j.1365-2036.2006.03042.x
Parnell JA, Reimer RA. Effect of prebiotic fibre supplemen-tation on hepatic gene expression and serum lipids: a dose-re-sponse study in JCR: LA-cp rats. Br J Nutr. 2010; 103: 1577- 1584. doi: 10.1017/S0007114509993539
Daubioul C, Rousseau N, Demeure R, et al. Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese Zucker fa/fa rats. J Nutr. 2002; 132: 967-973.
Levrat MA, Rémésy C, Demigné C. High propionic acid fer-mentations and mineral accumulation in the cecum of rats adapt-ed to different levels of inulin. J Nutr. 1991; 121: 1730-1737.
Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysac-charides. Physiol Rev. 2001; 81: 1031-1064.
Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endo-toxaemia. Diabetologia. 2007; 50: 2374-2383. doi: 10.1007/ s00125-007-0791-0
Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mecha-nism involving GLP-2-driven improvement of gut permeability. Gut. 2009; 58: 1091-1103. doi: 10.1136/gut.2008.165886
Beylot M. Effects of inulin-type fructans on lipid metabo-lism in man and in animal models. Br J Nutr. 2007; 93: S163. doi: 10.1079/BJN20041339
Parnell J, Reimer R. Weight loss during oligofructose sup-plementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2013; 89: 1-19. doi: 10.3945/ajcn.2009.27465
Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008; 46 Suppl 2(Suppl 2): S58-S61; dis-cussion S144-S151. doi: 10.1086/523341
Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Pro-biotics as an emerging therapeutic strategy to treat NAFLD: fo-cus on molecular and biochemical mechanisms. J Nutr Biochem. 2011; 22: 699-711. doi: 10.1016/j.jnutbio.2010.10.002
Ma Y-Y, Li L, Yu C-H, Shen Z, Chen L-H, Li Y-M. Effects of probiotics on Non-alcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013; 19: 6911-6918. doi: 10.3748/wjg. v19.i40.6911
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.